Skip to main content
HR 2368 115th Congress House Health Civil actions and liability Drug safety, medical device, and laboratory regulation Drug therapy Health personnel Health technology, devices, supplies Licensing and registrations Long-term, rehabilitative, and terminal care Medical tests and diagnostic methods Prescription drugs Product safety and quality

Right to Try Act

Introduced: July 17, 2017 Introduced by: Fitzpatrick, Brian K. Republican · Pennsylvania See on congress.gov
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 7, 2017
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Jun 7, 2017
Referred to the Subcommittee on the Constitution and Civil Justice.
May 5, 2017
Referred to the Subcommittee on Health.
May 4, 2017
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 4, 2017
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Right to Try Act

This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation.

A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.

The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.

The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.

What's happening now June 7, 2017

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

 Related & companion bills 2
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 5
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2368: Right to Try Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-2368/
MLA
"H.R. 2368: Right to Try Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-2368/.
Bluebook (legal)
H.R. 2368, 115th Cong. (2026), https://openamerica.io/bill/115-HR-2368/.
Markdown link
[H.R. 2368: Right to Try Act](https://openamerica.io/bill/115-HR-2368/)
Report a problem